# EDGAR Filing Document

**Accession Number:** 0001770069
**File Stem:** 0001193125-26-125105
**Filing Date:** 2026-3
**Character Count:** 22678
**Document Hash:** e15d09715a75a9888ed48327e7a931bc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-125105.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0001193125-26-125105

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260326

**DATE AS OF CHANGE**: 20260326

**EFFECTIVENESS DATE**: 20260326

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MapLight Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001770069
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832163243
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294620
- **FILM NUMBER:** 26794379

**BUSINESS ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-839-4360

**MAIL ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alvarado Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20190307

**As filed with the Securities and Exchange Commission on March 26, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## MapLight Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **83-2163243** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **800 Chesapeake Drive**<br> **Redwood City, California 94063** | **94063** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**MapLight Therapeutics, Inc. 2025 Equity Incentive Plan** 

**MapLight Therapeutics, Inc. 2025 Employee Stock Purchase Plan** 

**(Full titles of the plans)** 

**Christopher A. Kroeger, M.D.** 

**Chief Executive Officer** 

**MapLight Therapeutics, Inc.** 

**800 Chesapeake Drive** 

**Redwood City, California 94063** 

**(617) 984-6300** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Christian E. Plaza** 

**Mark Ballantyne** 

**Cooley LLP** 

**11951 Freedom Drive** 

**Reston, Virginia 20190** 

**(703) 456-8000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This registration statement on Form S-8 (this "Registration Statement") registers an aggregate of 2,641,444 shares of common stock, par value $0.0001 per share ("common stock"), of MapLight Therapeutics, Inc. (the "Registrant") consisting of (i) 2,201,204 additional shares of common stock issuable under the Registrant's 2025 Equity Incentive Plan (the "2025 Plan") by operation of a provision in the 2025 Plan providing for an automatic increase in the number of shares reserved and available for issuance under the 2025 Plan effective on January 1, 2026, and (ii) 440,240 additional shares of common stock issuable under the Registrant's 2025 Employee Stock Purchase Plan (the "2025 ESPP") by operation of a provision in the 2025 ESPP providing for an automatic increase in the number of shares reserved and available for issuance under the 2025 ESPP effective on January 1, 2026.

Pursuant to General Instruction E to Form S-8, this Registration Statement incorporates by reference the contents of the Registrant's registration statement on Form S-8 filed with the Securities and Exchange Commission (the "Commission") on [October 27, 2025 (File No. 333-291087](http://www.sec.gov/Archives/edgar/data/1770069/000119312525250723/d39918ds8.htm)), except to the extent supplemented, amended or superseded by the information set forth herein.

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the "Securities Act") and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

**PART II** 

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF DOCUMENTS BY REFERENCE**  |

---

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1770069/000119312526125072/mplt-20251231.htm) (File No. 001-42914) for the fiscal year ended December 31, 2025, filed with the Commission on March 26, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The description of the Registrant's Common Stock contained in [Exhibit 4.2](http://www.sec.gov/Archives/edgar/data/1770069/000119312526125072/mplt-ex4_2.htm) in the Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1770069/000119312526125072/mplt-20251231.htm) (File No. 001-42914) for the fiscal year ended December 31, 2025, filed with the Commission on March 26, 2026, including any amendment or report filed with the Commission for the purpose of updating such
description.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

------

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS**  |

---

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-42914) filed with the SEC on October 29, 2025).](http://www.sec.gov/Archives/edgar/data/1770069/000119312525255041/d89036dex31.htm) |
| 4.2 | [Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-42914) filed with the SEC on October 29, 2025).](http://www.sec.gov/Archives/edgar/data/1770069/000119312525255041/d89036dex32.htm) |
|  5.1\* | [Opinion of Cooley LLP.](d118127dex51.htm) |
|  23.1\* | [Consent of Independent Registered Public Accounting Firm.](d118127dex231.htm) |
|  23.2\* | [Consent of Cooley LLP (included in Exhibit 5.1).](d118127dex51.htm) |
|  24.1\* | [Power of Attorney (included on the signature page).](#sig) |
| 99.1 | [The Registrant's 2025 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Notice of Exercise, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-290400), filed with the Commission on October 6, 2025).](http://www.sec.gov/Archives/edgar/data/1770069/000119312525231829/d90027dex102.htm) |
| 99.2 | [The Registrant's 2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-290400), filed with the Commission on October 6, 2025).](http://www.sec.gov/Archives/edgar/data/1770069/000119312525231829/d90027dex103.htm) |
|  107\* | [Filing Fee Table.](d118127dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, California, on March 26, 2026.

---

| | |
|:---|:---|
| **MAPLIGHT THERAPEUTICS, INC.** | **MAPLIGHT THERAPEUTICS, INC.** |
| By: | /s/ Christopher A. Kroeger |
|  | Christopher A. Kroger, M.D. |
|  | Chief Executive Officer and Director |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher A. Kroeger, M.D., and Vishwas Setia, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Christopher A. Kroeger<br> Christopher A. Kroeger, M.D. | Chief Executive Officer and Director<br> (*Principal Executive Officer*) | March 26, 2026 |
| /s/ Vishwas Setia<br> Vishwas Setia | Chief Financial Officer<br> (*Principal Financial Officer*) | March 26, 2026 |
| /s/ Jonathan Gillis<br> Jonathan Gillis | Chief Administrative and Accounting Officer<br> (*Principal Accounting Officer*) | March 26, 2026 |
| /s/ Timothy Garnett<br> Timothy Garnett, M.B.B.S. | Director | March 26, 2026 |
| /s/ Nanna Lüneborg<br> Nanna Lüneborg, Ph.D. | Director | March 26, 2026 |
| /s/ Robert Malenka<br> Robert Malenka, M.D., Ph.D. | Director | March 26, 2026 |
| /s/ George Pavlov<br> George Pavlov | Director | March 26, 2026 |
| /s/ Jim Trenkle<br> Jim Trenkle, Ph.D. | Director | March 26, 2026 |
| /s/ Maria Walker<br> Maria Walker | Director | March 26, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g118127g0325015747981.jpg)

Mark Ballantyne

+1 703 456 8084

mballantyne@cooley.com

March 26, 2026

MapLight Therapeutics, Inc.

800 Chesapeake Drive

Redwood City, California 94063

We have acted as counsel to MapLight Therapeutics, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 2,641,444 shares (the "***Shares***") of the Company's common stock, par value $0.0001 per share ("***Common Stock***"), consisting of (a) 2,201,204 shares of Common Stock issuable pursuant to the Company's 2025 Equity Incentive Plan (the "***EIP***") and (b) 440,240 shares of Common Stock pursuant to the Company's 2025 Employee Stock Purchase Plan (the "***ESPP***" and together with the EIP, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectuses, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Plans and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

Cooley LLP One Freedom Square Reston Town Center 11951 Freedom Drive Reston, VA 20190-5640

t: (703) 456-8000 f: (703) 456-8100 cooley.com

------

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

---

| | |
|:---|:---|
| By: | /s/ Mark Ballantyne |
|  | Mark Ballantyne |

---

Cooley LLP One Freedom Square Reston Town Center 11951 Freedom Drive Reston, VA 20190-5640

t: (703) 456-8000 f: (703) 456-8100 cooley.com

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in this Registration Statement on Form S-8 of MapLight Therapeutics, Inc. of our report dated March 26, 2026, relating to the consolidated financial statements of MapLight Therapeutics, Inc. and its subsidiary, appearing in the Annual Report on Form 10-K of MapLight Therapeutics, Inc. for the year ended December 31, 2025.

/s/ RSM US LLP

Boston, Massachusetts

March 26, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**MapLight Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common stock, $0.0001 par value per share, 2025 Equity Incentive Plan | 457(a) | 2201204 | $16.83 | $37046263.32 | 0.0001381 | $5116.09 |
| 2 | Equity | Common stock, $0.0001 par value per share, 2025 Employee Stock Purchase Plan | 457(a) | 440240 | $14.31 | $6299834.40 | 0.0001381 | $870.01 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $43346097.72  |  | $5986.10  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $5986.10  |

---

 **Offering Note** <br>

<sup>1</sup> Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock of MapLight Therapeutics, Inc. (the "Registrant") that become issuable under the Registrant's 2025 Equity Incentive Plan (the "2025 Plan") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant's common stock, as applicable. The amount registered represents shares of common stock that were added to the shares reserved for future issuance under the 2025 Plan on January 1, 2026, pursuant to an evergreen provision contained in the 2025 Plan. Pursuant to such provision, the number of shares reserved for issuance under the 2025 Plan will automatically increase on January 1 of each year for a period of 10 years, beginning on January 1, 2026 and continuing through (and including) January 1, 2035, in an amount equal to 5% of the total number of shares of common stock of the Registrant equal to the sum of (i) the total number of shares of common stock and non-voting common stock issued and outstanding, and (ii) shares of common stock issuable upon exercise of outstanding pre-funded warrants outstanding on December 31 of the immediately preceding year, except that, before the date of any such increase, the Registrant's board of directors may determine that the increase for such year will be a lesser number of shares. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price for the shares of common stock being registered under the 2025 Plan are estimated in accordance with Rules 457(c) and 457(h) solely for the purpose of calculating the registration fee are based upon a per share price of $16.83, which is the average of the high and low selling prices per share of the Registrant's common stock on March 24, 2026 as reported on the Nasdaq Global Select Market.

<sup>2</sup> Pursuant to Rule 416(a) promulgated under the Securities Act, this Registration Statement shall also cover any additional shares of common stock of the Registrant that become issuable under the Registrant's 2025 Employee Stock Purchase Plan (the "2025 ESPP") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant's common stock, as applicable. The amount registered represents shares of common stock that were added to the shares reserved for future issuance under the 2025 ESPP on January 1, 2026, pursuant to an evergreen provision contained in the 2025 ESPP. Pursuant to such provision, the number of shares reserved for issuance under the 2025 ESPP will automatically increase on January 1 of each year for a period of 10 years, beginning on January 1, 2026 and continuing through (and including) January 1, 2035, by the lesser of (x) 1% of the total number of shares of common stock of the Registrant equal to the sum of (i) the total number of shares of common stock and non-voting common stock issued and outstanding, and (ii) shares of common stock issuable upon exercise of outstanding pre-funded warrants outstanding on December 31 of the immediately preceding year and (y) 900,000 shares, except that, before the date of any such increase, the Registrant's board of directors may determine that the increase for such year will be a lesser number of shares. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price for the shares of common stock being registered under the 2025 ESPP are estimated in accordance with Rules 457(c) and 457(h) solely for the purpose of calculating the registration fee. The offering price per share and the aggregate offering price are based upon a per share price of $14.31, which is the average of the high and low selling prices per share of the Registrant's common stock on March 24, 2026 as reported on the Nasdaq Global Select Market multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2025 ESPP.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---